Topics

Companies Related to "Caspase receptor interacting protein kinase RIPK1 RIPK3 regulate" [Most Relevant Company Matches] RSS

19:31 EST 9th December 2019 | BioPortfolio

Here are the most relevant search results for "Caspase receptor interacting protein kinase RIPK1 RIPK3 regulate" found in our extensive corporate database of over 50,000 company records.

Showing "Caspase receptor interacting protein kinase RIPK1 RIPK3 regulate" Companies 1–25 of 1,100+

Extremely Relevant

PanVera Corporation

Protein Kinase C Assays Androgen Receptor, Ligand Binding Domain Estrogen Receptor-Beta 1, Long Form Tau Protein, microtubule-associated protein, histidine-tagged Cytochrome P450 Monoclonal Antibodiesa broad selection of antibodies can be found here.


ArQule, Inc.

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 clinical development, is ARQ 197, an in...

Relevant

GloboZymes

GloboZymes is a leading provider of top quality signal transduction enzymes, proteins and antibodies.We maintain a cell signaling, cancer and apoptosis-related research program. Our purified protein kinase, protein phosphatase, protein kinase substrate, modulator protein, protein synthesis initiation factor and affinity-purified antibody preparations generally exhibit greater than 90% homogeneity ...


SGX Pharmaceuticals, Inc.

SGX Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development and commercialization of novel, targeted therapeutics directed at addressing unmet medical needs in oncology. Our drug development programs target the MET receptor tyrosine kinase, an enzyme implicated in a broad array of cancers, and the BCR-ABL tyrosine kinase enzyme for the treatment of Chronic Myelog...

CellZome AG

Cellzome is a privately-owned drug discovery company identifying a new generation of kinase- targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads™, a proprietary technology for the screening and profiling of kinases in relevant cells and tissues. Cellzome's emerging pipeline includes a small molecule Histamine H4 receptor antagonist, ...

Receptor BioLogix

Receptor BioLogix, Inc. is a biopharmaceutical company focused on developing the first broad-spectrum anti-HER therapeutic, resulting from its program to commercialize a newly discovered class of protein therapeutics called Intron Fusion Proteins™ (IFP™) to treat cancer, autoimmune, metabolic and other diseases.

Receptor BioLogix, Inc.

Receptor BioLogix, Inc. is a biopharmaceutical company focused on developing the first broad-spectrum anti-HER therapeutic, resulting from its program to commercialize a newly discovered class of protein therapeutics called Intron Fusion Proteins™ (IFP™) to treat cancer, autoimmune, metabolic and other diseases.

Otava Ltd

OTAVA, Ltd. offers unique Receptor-Based Target-Focused libraries. These libraries are created from an extensive compound stock collection (490,000 compounds) and a rigorous process of refinement that involves harnessing the most current methods of theoretical medicinal chemistry. All of the Receptor-Based Target-Focused libraries of compounds are available in-house, and come with docking scores a...

Carna Biosciences, Inc.

Carna Biosciences, Inc. (www.carnabio.com), founded in April 2003, is a Japanese biotechnology company conducting intercellular signaling-based drug discovery programs, as well as providing drug discovery services to pharmaceutical companies, using proprietary technologies in gene cloning, active kinase protein expression, protein purification and homogeneous assay development.

Ziarco

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting inflammatory and allergic diseases. The company’s product pipeline includes ZPL-3893787, an H4 receptor antagonist that has completed a Phase 1 multiple ascending dose study. A second clinical-stage, programme targets inflammatory disorders by inhibiting cyto...

Angstrom Pharmaceuticals Incorporated

Ångstrom Pharmaceuticals, Inc. was formed in 1996 to add a new dimension to drug discovery. It is committed to discovering drugs that block the docking of an extracellular regulatory protein (ligand) to its receptor found on the outside of a cell – when this event is responsible for initiating a disease state. Receptors can be identified that trigger several intractable diseases including cance...

Receptos, Inc.

Receptos is a biopharmaceutical company developing best- and first-in-class G protein-coupled receptor (GPCR) therapeutic candidates through information-driven drug discovery, including GPCR structure determination. The company’s lead program is a best-in-class S1P1 small molecule, agonist candidate for autoimmune indications, including multiple scler...

Proteinlounge

Protein Lounge is a leader in the field of system biology. We have developed many interactive web-based databases and software to help the life-scientists understand the complexity of systems biology. Systems biology efforts focus on understanding cellular networks, protein interactions involved in cell signaling, mechanisms of cell survival and apoptosis leading to development or identification o...

Kinex Pharmaceuticals, LLC

Kinex Pharmaceuticals is developing next generation anti-cancer drugs that target the molecular basis of disease. The Company uses a proprietary technology platform to generate compounds that inhibit the Protein Kinase and Phosphatase family of proteins.Protein kinases and phosphatases are families of proteins that are intimately involved in transmitting signals across the cell membrane. They cont...

ProQinase GmbH

ProQinase GmbH was founded in 2001 as a 100% subsidiary of the Tumor Biology Center Freiburg, which is one of the largest privately owned hospitals of this type in Europe. ProQinase has been growing steadily over the past years. It has meanwhile a personal of 29 and offers its Integrated Protein Kinase Technology Platform, which is uniquely designed for drug development targeting protein kinases i...

ConfometRx

ConfometRx is pioneering a platform of structure-based drug development tools that facilitate target validation, lead identification, and lead optimization for G protein coupled receptor (GPCR) targets. This platform includes biochemical and biophysical technologies for defining drug binding sites; the production of pure, functional GPCRs for high-resolution structure determination by crystallogra...

Ambit Biosciences Corporation

Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit employs a novel and proprietary kinase profiling technology, KINOMEscan(TM), to screen compounds against 442 human kinases.

Arrien Pharmaceuticals

Arrien Pharmaceuticals is a targeted therapeutics drug discovery and development company. Arrien applies its proprietary fragment-based FIELDS drug discovery technology to target kinase signaling and nuclear receptor pathways, which are critical pathways in inflammation, autoimmune diseases, cancer, and neurodegenerative diseases. Arrien has developed a...

Acceleron Pharma, Celgene Corporation

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair. The company is a leader in understanding the biology of the TGF-beta protein superfamily, a large and diverse group of molecules that are key regulators in the growth a...

Receptor Biology Incorporated

Receptor Biology Inc. produce cloned receptors for pharmacology studies and drug discovery, products include adenosine, cannabinoid, dopamine, muscarinic, serotonin, opoid, bradykinin, transporter, wild type.

Acceleron Pharma & Celgene Corporation

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair. The company is a leader in understanding the biology of the TGF-beta protein superfamily, a large and diverse group of molecules that are key regulators in the growth a...

Message Pharmaceuticals Incorporated

MESSAGE PHARMACEUTICALS, INC. is an emerging biotechnology company dedicated to developing novel and proprietary screening assays for discovering new drugs. Currently, most drugs act by binding to specific sequences and structures within a target protein, such as a receptor or enzyme, and altering the protein's activity or function. MESSAGE's technology will allow for the identification of drugs...

Evolutec Group plc

Evolutec discovers and develops novel biopharmaceuticals for allergic, anti-inflammatory and auto-immune diseases. Evolutec has progressed its lead therapeutic molecule, rEV131, a novel histamine binding protein, from discovery to completion of initial Phase II clinical trials in allergic conjunctivitis, rhinitis and ocular inflammation. Positive preclinical data has also been generated in asthma ...

Cellzome Inc.

Cellzome is a privately-owned drug discovery and development company identifying a new generation of kinase-targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads(TM), a proprietary technology for the screening and profiling of kinase inhibitors in physiologically-relevant cells and tissues. The most advanced program, targeting PI3K(ga...

ProteoChem, Inc.

ProteoChem manufactures protein crosslinkers, analytical standards, and novel proteomics reagents for protein detection and protein modification that are used in mass spectrometry, drug development, diagnostics, and protein biology.


More From BioPortfolio on "Caspase receptor interacting protein kinase RIPK1 RIPK3 regulate"

Quick Search

Corporate Database Quicklinks